CAR-Ts Getting Boxed Warning On Secondary Malignancies Despite Sponsor Causation Questions

Sponsors still say they have no evidence the CAR-Ts cause secondary malignancy even though US FDA ordered their labels updated with a boxed warning of the adverse event. Tecartus label will not state that postmarketing secondary malignancies have been found in patients using the product.